HKD24.85
5.33% yesterday
Hong Kong, Apr 03, 10:08 am CET
ISIN
KYG970081173
Symbol
2269
Index
Sector
Industry

WuXi Biologics Target price 2025 - Analyst rating & recommendation

WuXi Biologics Classifications & Recommendation:

Buy
67%
Hold
33%

WuXi Biologics Price Target

Target Price HKD29.76
Price HKD24.85
Potential
Number of Estimates 24
24 Analysts have issued a price target WuXi Biologics 2026 . The average WuXi Biologics target price is HKD29.76. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 27 analysts: 18 Analysts recommend WuXi Biologics to buy, 9 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the WuXi Biologics stock has an average upside potential 2026 of . Most analysts recommend the WuXi Biologics stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Billion HKD 20.25 22.58
7.57% 11.51%
EBITDA Margin 33.44% 35.00%
7.10% 4.67%
Net Margin 18.05% 19.10%
8.07% 5.83%

27 Analysts have issued a sales forecast WuXi Biologics 2025 . The average WuXi Biologics sales estimate is

HKD22.6b
Unlock
. This is
11.51% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HKD23.1b 14.32%
Unlock
, the lowest is
HKD20.9b 3.43%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 HKD20.2b 7.57%
2025
HKD22.6b 11.51%
Unlock
2026
HKD26.0b 15.33%
Unlock
2027
HKD30.3b 16.24%
Unlock
2028
HKD31.4b 3.77%
Unlock

19 Analysts have issued an WuXi Biologics EBITDA forecast 2025. The average WuXi Biologics EBITDA estimate is

HKD7.9b
Unlock
. This is
16.70% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
HKD9.4b 38.48%
Unlock
, the lowest is
HKD7.0b 3.68%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 HKD6.8b 15.21%
2025
HKD7.9b 16.71%
Unlock
2026
HKD9.2b 16.64%
Unlock
2027
HKD10.7b 16.21%
Unlock
2028
HKD11.0b 3.02%
Unlock

EBITDA Margin

2024 33.44% 7.10%
2025
35.00% 4.67%
Unlock
2026
35.40% 1.14%
Unlock
2027
35.39% 0.03%
Unlock
2028
35.13% 0.73%
Unlock

24 WuXi Biologics Analysts have issued a net profit forecast 2025. The average WuXi Biologics net profit estimate is

HKD4.3b
Unlock
. This is
18.04% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
HKD5.7b 55.48%
Unlock
, the lowest is
HKD3.8b 4.62%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 HKD3.7b 1.11%
2025
HKD4.3b 18.04%
Unlock
2026
HKD5.1b 18.27%
Unlock
2027
HKD6.1b 18.81%
Unlock
2028
HKD6.6b 8.85%
Unlock

Net Margin

2024 18.05% 8.07%
2025
19.10% 5.83%
Unlock
2026
19.59% 2.57%
Unlock
2027
20.02% 2.19%
Unlock
2028
21.00% 4.90%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share HKD 0.89 1.05
1.11% 17.98%
P/E 23.65
EV/Sales 4.42

24 Analysts have issued a WuXi Biologics forecast for earnings per share. The average WuXi Biologics EPS is

HKD1.05
Unlock
. This is
17.98% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
HKD1.38 55.06%
Unlock
, the lowest is
HKD0.93 4.49%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 HKD0.89 1.11%
2025
HKD1.05 17.98%
Unlock
2026
HKD1.24 18.10%
Unlock
2027
HKD1.48 19.35%
Unlock
2028
HKD1.61 8.78%
Unlock

P/E ratio

Current 27.88 77.35%
2025
23.65 15.17%
Unlock
2026
20.00 15.43%
Unlock
2027
16.83 15.85%
Unlock
2028
15.47 8.08%
Unlock

Based on analysts' sales estimates for 2025, the WuXi Biologics stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.93 61.11%
2025
4.42 10.35%
Unlock
2026
3.83 13.29%
Unlock
2027
3.30 13.97%
Unlock
2028
3.18 3.64%
Unlock

P/S ratio

Current 5.04 55.89%
2025
4.52 10.32%
Unlock
2026
3.92 13.29%
Unlock
2027
3.37 13.97%
Unlock
2028
3.25 3.63%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today